Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01272063
Other study ID # HD-OCT-DR-2010-1
Secondary ID
Status Completed
Phase N/A
First received January 5, 2011
Last updated June 24, 2013
Start date November 2010
Est. completion date February 2011

Study information

Verified date June 2013
Source Carl Zeiss Meditec, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).


Description:

This is a prospective, multiple site study. Ocular history and examination will be conducted on consented subjects to determine further participation in the study. Subjects qualified to continue will undergo color fundus photography and imaging of their study eye using the Cirrus HD-OCT.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date February 2011
Est. primary completion date February 2011
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Males or females 50 years of age or older diagnosed to have dry AMD with macular drusen.

- Drusen should not be combined with other lesions such as geographic atrophy (GA) or choroidal neovascularization.

- Able and willing to make the required study visits.

- Able and willing to give consent and follow study instructions.

Exclusion Criteria:

- History of retinal surgery, laser photocoagulation, and/or radiation therapy to the eye.

- Evidence of other retinal diseases of the eye, including wet AMD, diabetic retinopathy, diabetic macular edema, or significant vitreomacular traction upon dilated examination, or upon evaluation of retinal photos.

- Thick media opacity or inability to fixate that precludes obtaining acceptable scans.

- Concomitant use of hydrochloroquine and chloroquine.

- Unable to make the required study visits.

- Unable to give consent or follow study instructions.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States TLC Eyecare and Laser Centers Lansing Michigan
United States Bascom Palmer Eye Institute Miami Florida
United States East Bay Retina Oakland California
United States West Coast Retina San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Carl Zeiss Meditec, Inc. DataMed Devices Inc.

Country where clinical trial is conducted

United States, 

References & Publications (9)

Ahlers C, Götzinger E, Pircher M, Golbaz I, Prager F, Schütze C, Baumann B, Hitzenberger CK, Schmidt-Erfurth U. Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2149-57. doi: 10.1167/iovs.09-3817. Epub 2009 Sep 24. — View Citation

Friberg TR, Huang L, Palaiou M, Bremer R. Computerized detection and measurement of drusen in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2007 Mar-Apr;38(2):126-34. — View Citation

Jain N, Farsiu S, Khanifar AA, Bearelly S, Smith RT, Izatt JA, Toth CA. Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4875-83. doi: 10.1167/iovs.09-4962. Epub 2010 Apr 14. — View Citation

Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, Pankow JS, Klein BE. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010 Jun;128(6):750-8. doi: 10.1001/archophthalmol.2010.92. — View Citation

Munch IC, Ek J, Kessel L, Sander B, Almind GJ, Brøndum-Nielsen K, Linneberg A, Larsen M. Small, hard macular drusen and peripheral drusen: associations with AMD genotypes in the Inter99 Eye Study. Invest Ophthalmol Vis Sci. 2010 May;51(5):2317-21. doi: 10.1167/iovs.09-4482. Epub 2009 Dec 10. — View Citation

Stopa M, Bower BA, Davies E, Izatt JA, Toth CA. Correlation of pathologic features in spectral domain optical coherence tomography with conventional retinal studies. Retina. 2008 Feb;28(2):298-308. doi: 10.1097/IAE.0b013e3181567798. Erratum in: Retina. 2011 Jun;31(6):1236. — View Citation

Varma R, Azen SP, McKean-Cowdin R, Paz SH, Torres M, Barrera J, Choudhury F, Cisneros L, Chung J, Corona E, Cuestas C, Dzekov J, Foong AW, Lastra C, Lai MY, Martinez G, Shtir C, Smith RE, Tetrow L, Wang Y, Wu J, John L, Tucker K, Klein R, Meuer SE, Knutson MD, Neider M. Four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010; 149(5):741-51.

Wojtkowski M, Sikorski BL, Gorczynska I, Gora M, Szkulmowski M, Bukowska D, Kaluzny J, Fujimoto JG, Kowalczyk A. Comparison of reflectivity maps and outer retinal topography in retinal disease by 3-D Fourier domain optical coherence tomography. Opt Express. 2009 Mar 2;17(5):4189-207. — View Citation

Yi K, Mujat M, Park BH, Sun W, Miller JW, Seddon JM, Young LH, de Boer JF, Chen TC. Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration. Br J Ophthalmol. 2009 Feb;93(2):176-81. doi: 10.1136/bjo.2008.137356. Epub 2008 Aug 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other To describe the qualitative similarities and differences between the areas designated as elevated RPE by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs. Study was released before December 1, 2012 No
Primary To compare area measurements of elevated RPE as observed in the Cirrus HD-OCT versus those designated as drusen on color fundus photographs. Study was released before December 1, 2012 No
Secondary To describe the clinical factors that affected the automated segmentation of elevated RPE by the Cirrus HD-OCT. Study was released before December 1, 2012 No
See also
  Status Clinical Trial Phase
Recruiting NCT05056025 - Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration. N/A